Lazaros Lekakis, MD
Hematology & Oncology · Miami, FLNPI 1326067596
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,640 of the $33,323 with a category attached, or 82.9%. 20 manufacturers reported payments, led by Gilead at 45.5% of the total. 2025 is the largest year on record at $16,361, 2.2 times the $7,290 reported in 2019.
Across 92 payments — averaging $362.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$15K
- Sanofi-aventis U.S. LLC$8K
- Jazz Pharmaceuticals Inc.$5K
- Johnson & Johnson$1K
- Daiichi Sankyo Inc.$680
- Incyte Corporation$593
- plus $2K from 14 others
Across 222 payments — averaging $5498.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$461K
- Gilead$319K
- Incyte Corporation$241K
- Iovance Biotherapeutics, Inc.$86K
- Takeda Pharmaceuticals U.S.A., Inc.$43K
- Autolus Inc$32K
- plus $39K from 3 others
What the payments were for
- Consulting fees$27,64083%
- Travel & lodging$1,5705%
- Food & beverage$3,72411%
- Education$3891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 14 | $15,178 |
| Sanofi-aventis U.S. LLC | 8 | $8,299 |
| Jazz Pharmaceuticals Inc. | 3 | $5,412 |
| Johnson & Johnson | 5 | $1,167 |
| Daiichi Sankyo Inc. | 2 | $680 |
| Incyte Corporation | 10 | $593 |
| Genetix Biotherapeutics Inc | 6 | $583 |
| E.r. Squibb & Sons, L.L.C. | 9 | $271 |
| Legend Biotech USA Inc. | 3 | $254 |
| Astellas Pharma US Inc | 3 | $161 |
| Beigene USA, Inc. | 1 | $125 |
| Novartis | 6 | $124 |
| Iovance Biotherapeutics, Inc. | 1 | $109 |
| Bristol Myers Squibb | 5 | $96 |
| Pfizer | 5 | $93 |
| Seagen Inc. | 4 | $56 |
| Merck | 2 | $45 |
| AstraZeneca | 3 | $40 |
| Verastem, Inc. | 1 | $22 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,323 in reported general payments places this provider in the 80th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Miami
- Steven FeinMiami$1M
- Srikanth NagallaMiami$639K
- Neil NagovskiMiami$530K
- Carl LandgrenMiami$517K
- Raja MudadMiami$422K
- George NahasMiami$364K
- Fernando de ZarragaMiami$333K
- Mikkael SekeresMiami$278K
- Krishna KomanduriMiami$187K
- Estelamari RodriguezMiami$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.